Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction
This article was originally published in The Tan Sheet
Executive Summary
House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.
You may also be interested in...
Tiger Balm External Analgesic Firm Scratched Again On US GMP Violations
Inspection in February and March found GMP violations including failing to thoroughly investigate unexplained batch discrepancies or failures, regardless of whether it already is distributed, are repeats from 2010 problems FDA found at Haw Par Healthcare.
OTC Device Claims For COPD ‘Therapy’ Put Patients At Risk – UK Regulator
ASA finds device marketer BioLife Solutions could not rely on a disclaimer and use of the word “therapy” instead of “treatment” to offset the message its Airnergy device treats a medical condition. ASA advices not to make COPD treatment claims unless a product is properly certified.
OTC Device Claims For COPD ‘Therapy’ Put Patients At Risk – UK Regulator
ASA finds device marketer BioLife Solutions could not rely on a disclaimer and use of the word “therapy” instead of “treatment” to offset the message its Airnergy device treats a medical condition. ASA advices not to make COPD treatment claims unless a product is properly certified.